Insulin analogs are modified versions of human insulin, the two-chain peptide hormone that lowers blood glucose. Swapping one or two amino acids, or attaching a fatty acid, changes how fast or how long they act. This guide covers six main analogs: their structure, mechanism, FDA-labeled use, outcome trials and label warnings. Sources were checked on November 17, 2026.
Quick answer: Insulin analogs are prescription biologics labeled “to improve glycemic control” in diabetes mellitus. Rapid-acting analogs include lispro, aspart and glulisine. Long-acting analogs include glargine, detemir and degludec. Hypoglycemia is the main risk. None of the six labels reviewed here has a boxed warning.
Vitrapep does not sell insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin detemir or insulin degludec; this page is a reference summary of published research and regulatory information.
What are insulin analogs?
Human insulin has two peptide chains. ChEBI text in PubChem says it “consists of two peptide chains, one containing 21 amino acid residues and the other containing 30.” The chains “are joined together by 2 disulfide bonds” (PubChem CID 118984375). Labels call the shorter one the A chain and the longer one the B chain. An analog keeps this frame but changes specific positions.
Is insulin a peptide? Chemically, yes: it is built from amino acid chains. For regulation, FDA counts the total amino acids in chains that associate naturally. A polymer “greater than 40 amino acids in size” is a protein (21 CFR 600.3). With 51 amino acids across two chains, insulin falls on the protein side. Our peptide vs protein explainer covers that line.
The Humalog and Lantus labels describe production in Escherichia coli by recombinant DNA technology. Drugs@FDA shows each of the six original NDAs was “Deemed To Be a BLA on March 23, 2020” (Drugs@FDA).
Insulin analogs: key facts
| Analog | Class | Change from human insulin (label) | Molecular weight (label) | Brand and first FDA approval |
|---|---|---|---|---|
| Insulin lispro | Rapid-acting | B28 proline and B29 lysine swapped | 5.808 kDa | Humalog (Lilly), June 14, 1996 |
| Insulin aspart | Rapid-acting | B28 proline replaced by aspartic acid | 5,825.8 Da | NovoLog (Novo Nordisk), June 7, 2000 |
| Insulin glulisine | Rapid-acting | B3 asparagine to lysine; B29 lysine to glutamic acid | 5.823 kDa | Apidra (Sanofi), April 16, 2004 |
| Insulin glargine | Long-acting | A21 asparagine to glycine; two arginines added to the B chain end | 6,063 Da | Lantus (Sanofi), April 20, 2000 |
| Insulin detemir | Long-acting | B30 threonine removed; C14 fatty acid on B29 | 5.917 kDa | Levemir (Novo Nordisk), June 16, 2005 |
| Insulin degludec | Long-acting | B30 threonine removed; glutamic acid plus C16 fatty acid side chain | 6.104 kDa | Tresiba (Novo Nordisk), September 25, 2015 |
How do insulin analogs work?
Every analog does the same basic job as human insulin. The Humalog label states: “Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro.” Insulins lower blood glucose by stimulating glucose uptake into skeletal muscle and fat (Humalog label, 2026). The Lantus label adds that insulin inhibits glucose production by the liver. It also inhibits fat and protein breakdown and enhances protein synthesis (Lantus label, 2025).
The differences are about timing. For detemir, the Levemir label credits slowed absorption to “self-association of the drug molecules.” Binding to albumin also slows its spread to tissues (Levemir label, 2024). For degludec, the Tresiba label says it “forms multi-hexamers,” and that its long action is “predominantly due to delayed absorption” (Tresiba label, 2022). Our half-life explainer covers the general idea.
What are insulin analogs approved for?
The labels use nearly identical wording. Humalog, NovoLog, Apidra, Lantus and Levemir are each indicated “to improve glycemic control in adult and pediatric patients with diabetes mellitus” (NovoLog says “adults”). Tresiba is indicated to improve glycemic control “in patients 1 year of age and older with diabetes mellitus.” The Lantus and Tresiba labels add a limitation: they are not recommended for diabetic ketoacidosis (NovoLog label, 2023; Apidra label, 2025).
What did the key trials show?
DEVOTE (degludec vs glargine). This double-blind, event-driven human trial randomized 7,637 patients with type 2 diabetes at high cardiovascular risk. Major adverse cardiovascular events occurred in 8.5% with degludec and 9.3% with glargine. The hazard ratio was 0.91 (95% CI, 0.78 to 1.06), meeting the test for noninferiority. Severe hypoglycemia occurred in 4.9% versus 6.6% of patients (Marso et al., 2017; NCT01959529).
ORIGIN (glargine vs standard care). This randomized human trial enrolled 12,537 people with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance or type 2 diabetes. Glargine had a neutral effect on the first coprimary outcome of heart attack, stroke or cardiovascular death. The rates were 2.94 versus 2.85 per 100 person-years (hazard ratio 1.02; 95% CI, 0.94 to 1.11). Severe hypoglycemia was more common with glargine: 1.00 versus 0.31 per 100 person-years (ORIGIN Trial Investigators, 2012; NCT00069784).
What side effects does the label list?
None of the six labels reviewed has a boxed warning. The Humalog label lists hypoglycemia, allergic reactions, lipodystrophy, itching and rash among associated reactions. The Lantus label lists the same and adds edema and weight gain. The Humalog label is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin lispro.
The Humalog and Lantus labels share these warnings:
- high or low blood glucose after changes in insulin treatment;
- hypoglycemia, including hypoglycemia due to medication errors;
- hypersensitivity reactions and low potassium (hypokalemia); and
- fluid retention and heart failure with PPAR-gamma agonists (thiazolidinediones).
The Humalog label also warns of high blood glucose and ketoacidosis if an insulin pump fails (Humalog label, 2026).
What is the regulatory status of insulin analogs, and how are they used in research?
Insulin analogs are prescription biologics in the United States. FDA’s biosimilar product list includes Semglee and Rezvoglar (insulin glargine, 2021) and Merilog and Kirsty (insulin aspart, 2025). It also lists Langlara (insulin glargine, April 2026) and Garzulys (insulin aspart, July 2026). Semglee’s entry links to an FDA announcement of the first interchangeable biosimilar insulin (FDA, 2026). The research summarized here is clinical: large human outcome trials.
Frequently asked questions about insulin analogs
Is insulin a peptide?
It is a peptide hormone made of two chains of 21 and 30 amino acids. Because the total exceeds 40, FDA rules class it as a protein.
What was the first insulin analog?
Insulin lispro. Drugs@FDA lists the original approval of Humalog on June 14, 1996.
What makes a long-acting analog last longer?
It depends on the analog. Labels describe self-association and albumin binding for detemir, and multi-hexamer formation for degludec.
Are there biosimilar insulin analogs?
Yes. FDA lists glargine and aspart biosimilars, starting with Semglee in July 2021.
Do insulin analogs have a boxed warning?
None of the six labels reviewed has one. Hypoglycemia is the main warning across all of them.
What to know now
- Structure: human insulin’s two chains (21 and 30 amino acids) with targeted changes.
- Approval: Humalog first, June 14, 1996; all deemed biologics on March 23, 2020.
- Mechanism: regulate glucose metabolism; structural changes alter timing.
- Evidence: DEVOTE HR 0.91 for degludec vs glargine; ORIGIN HR 1.02 for glargine vs standard care.
- Safety: no boxed warnings; hypoglycemia is the key risk.
What we’re watching
Additions to FDA’s biosimilar product list, which gained Langlara and Garzulys in 2026. Related guides: mecasermin, glucagon and semaglutide.